Neuro-Oncology News

The addition of the novel monoclonal antibody hu14.18K322A to induction chemotherapy significantly improved outcomes among children with newly diagnosed high-risk neuroblastoma, according to phase 2 study results.

Adolescent and young adult patients with central nervous system tumors who lived farther from the reporting hospital had a lower risk for death than those who lived closer, according to study results published in Journal of Neuro-Oncology.

Increasing diagnoses of paraneoplastic neurologic syndromes in the U.S. correlates to heightened awareness by physicians as well as greater testing availability, according to a population-based epidemiology study published in Neurology: Neuroimmunology & Neuroinflammation.

The FDA granted orphan drug designation to silmitasertib for treatment of medulloblastoma.

Surgeons at Lenox Hill Hospital are recruiting patients for a first-in-human, single arm, open-label phase 1 clinical trial investigating the safety and feasibility of using belly fat to treat recurrent glioblastoma.

Circulating tumor DNA can be readily detected in patients with central nervous system lymphoma and may be a strong clinical biomarker for risk stratification, outcomes prediction and surgery-free lymphoma classification, results showed.

Christian S. Hinrichs, MD, is reluctant to give cancer credit for anything good.

Tumor gene expression profiles have become standard practice to help guide treatment of several cancer types.

A personalized cancer vaccine conferred a PFS benefit to a subset of patients with newly diagnosed glioblastoma, according to phase 2 study results presented at Society for the Immunotherapy of Cancer Annual Meeting.

John F. de Groot, MD, has been appointed chief of the neuro-oncology division at University of California, San Francisco.